WO1998052540A1 - Pharmaceutical compositions - Google Patents
Pharmaceutical compositions Download PDFInfo
- Publication number
- WO1998052540A1 WO1998052540A1 PCT/EP1998/003179 EP9803179W WO9852540A1 WO 1998052540 A1 WO1998052540 A1 WO 1998052540A1 EP 9803179 W EP9803179 W EP 9803179W WO 9852540 A1 WO9852540 A1 WO 9852540A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nsaid
- compound
- throat
- therapeutically effective
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Definitions
- the present invention relates to pharmaceutical compositions containing certain non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs also having analgesic and antipyretic activity.
- NSAIDs non-steroidal anti-inflammatory drugs
- the invention also relates to the use of these new pharmaceutical formulations in the treatment of the symptoms of cold and flu particularly sore throat.
- Some NSAID molecules exist in two enantiomeric forms and the term NSAID as used herein is intended to embrace the individual enantiomers and mixtures thereof in any proportion including a 1 :1 mixture which is herein referred to as the racemic form.
- NSAIDs can exist in the form of pharmaceutically acceptable salts or in the form of derivatives such as esters and such salts or esters are embraced by the term "NSAID" as used herein.
- a first aspect of the present invention provides the use of an NSAID selected from ketoprofen, diclofenac, piroxicam and indomethacin in the treatment of sore throats which use comprises the administration to a patient in need of such treatment of a pharmaceutical composition in the form of a masticable or suckable solid dosage form or a liquid or a spray containing a therapeutically effective amount of said NSAID which releases the said NSAID in the oral cavity so as to deliver the said NSAID to the surface of the sore throat.
- NSAID selected from ketoprofen, diclofenac, piroxicam and indomethacin
- a further aspect of the present invention provides pharmaceutical compositions comprising a combination of a therapeutically effective amount of an NSAID selected from ibuprofen, naproxen, ketoprofen, diclofenac, piroxicam and indomethacin with a therapeutically effective amount of one or more active ingredients selected from an antihistami ⁇ e, a cough suppressant, a decongestant, an expectorant, a muscle relaxant, a centrally acting analgesic, a local anaesthetic, an antibacterial compound, an antiviral compound, an antibiotic compound, an antifungal compound, minerals and vitamins in the form of a masticable or suckable solid dosage form or a liquid or a spray.
- an NSAID selected from ibuprofen, naproxen, ketoprofen, diclofenac, piroxicam and indomethacin
- active ingredients selected from an antihistami ⁇ e, a cough suppressant, a decongestant, an expectorant,
- Suitable antihistamines include acrivastine, azatadine, buclizine, cetirizine, cinnarizine, clemastine, loratidine and pharmaceutically acceptable salts thereof.
- Suitable cough suppressants include codeine, dextromethorphan or pholcodine and pharmaceutically acceptable salts thereof.
- Suitable decongestants include pseudoephedrine, phenylpropanolamine and phenylephrine and pharmaceutically acceptable salts thereof.
- Suitable expectorant include acetylcysteine, ammonium chloride, carbocysteine, guaifensin and potassium citrate.
- a suitable muscle relaxant is methocarbamol.
- Suitable centrally acting analgesics include codeine and its salts and hydrocodone.
- Suitable local anaesthetics include benzocaine, lignocaine, mepivacaine, prilocaine and pharmaceutically acceptable salts thereof.
- Suitable antibacterial compounds include amylmetacresol, dichlorobenzyl alcohol, quaternary ammonium compounds such as cetrimide, or benzalkonium chloride.
- Suitable antiviral compounds include zinc salts (for example the acetate, gluconate and ascorbate salts), acyclovir and its sodium salt.
- a suitable antibiotic is metronidazole.
- Suitable antifungal compounds include nystatin, amphotericin, imidazoles such as miconazole and triazoles such as fluconazole.
- Suitable minerals include zinc and selenium salts.
- Suitable vitamins include vitamins A, C, D, E and K, sodium ascorbate, riboflavine and thiamine hydrochloride.
- a further aspect of the present invention provides pharmaceutical compositions comprising a combination of a therapeutically effective amount of an NSAID selected from ibuprofen, naproxen, ketoprofen, diclofenac, piroxicam and indomethacin with a burn-masking amount of an agent which has a warming effect on the mucosa of the throat in the form of a masticable or suckable solid dosage form or a liquid or a spray.
- Suitable warming agents include ginger, chilli and agents containing or consisting of anethole.
- Anethole (1-methoxy-4-(1-propenyl)benzene or p-propenylanisole) is found naturally as the chief constituent of anise oil, star anise oil and fennel oil. It can be incorporated into the compositions in the present invention in substantially pure form, produced either by extraction from the above oils or synthetically, or it may be incorporated as one of the above oils. The amount of anethole should be such that the required amount of taste masking is obtained.
- compositions of the present invention are intended for use in the treatment of the symptoms of colds and flu particularly sore throat by the administration to a patient in need thereof of a pharmaceutical composition according to the present invention in the form of a masticable or suckable solid dosage form or a liquid or a spray containing a therapeutically effective amount of said NSAID which releases the said NSAID and any active ingredient and/or burn-masking agent that is present in the oral cavity so as to deliver the said NSAID, active ingredient(s) and/or burn-masking agent to the surface of the sore throat.
- the solid dosage form may be a lozenge which is intended to be sucked by the patient or a masticable or suckable tablet, capsule, pastille or gum, for example chewing gum.
- the term "lozenge” as used herein is intended to embrace all dosage forms where the product is formed by cooling a sugar-based or sugar alcohol based (eg isomalt) molten mass containing the active material.
- the term "tablet” as used herein is intended to embrace unit dosage forms made from compressed powders or granules or compressed pastes.
- a preferred pharmaceutical composition is a lozenge prepared by cooling a heated lozenge base containing the NSAID, active ingredient(s) and/or bum-masking agent and other excipients to form solid lozenges.
- the therapeutically effective amount of the NSAID when given in the absence of any other active ingredients has been found to be from 5% to 40% of the normal adult dose when given by ingestion to achieve a systemic antiinflammatory and/or analgesic effect.
- the NSAID may therefore be present in the pharmaceutical composition in an amount from 2.5 to 25 mg preferably 5 to 12.5 mg.
- the amount of the salt used should be such as to provide the desired amount of NSAID.
- Suitable salts include the alkali metal salts eg the sodium salt or amino acid salts eg the lysine, arginine or meglumine salts.
- the dose of piroxicam is in the range 15 to 25 mg, preferably 20 mg
- the dose of ketoprofen is 10 to 15 mg, preferably 12.5 mg
- the dose of indomethacin is 5 to 10 mg, preferably 6 mg
- the dose of diclofenac is 5 to 10 mg, preferably 6.25 mg.
- the amount of NSAID present may be in the range 2.5 to 200 mg.
- the preferred amounts of the NSAIDs listed above are as given above.
- the dose of ibuprofen or naproxen is in the range 50 to 200 mg when used in combination with one or more of the active ingredients listed above.
- NSAIDs would be expected to cause an unpleasant burning sensation at the back of the mouth when retained in the mouth. This would clearly be unacceptable to the patient being treated.
- the present applicants have surprisingly found that an unacceptable burning sensation is not experienced when the present invention is used to treat a sore throat but that the patient does receive relief of the symptoms of the sore throat.
- Solid dosage forms may be prepared by methods which are well known in the art for the production of lozenges, tablets, capsules or chewing gums and may contain other ingredients known in such dosage forms such as acidity regulators, opacifiers, stabilising agents, buffering agents, flavourings, sweeteners, colouring agents, buffering agents, flavourings, sweeteners, colouring agents and preservatives. Any additional ingredient which is added should not react with any other component of the pharmaceutical compositions of the present invention. If such interactions are possible the components concerned should be kept separate for example by encapsulating one or both of the possibly reacting components, by including one of the components in a coating applied to the lozenge after manufacture or by having the components in different layers of a multilayer product.
- flavour or component of the flavour or an excipient or carrier for the flavour contains an alcohol moiety
- esterification of the carboxylic acid moiety in the phenylpropionic acid NSAIDs can be prevented or minimised by the methods outline above.
- the preferred solid formulations of the present invention may be prepared as lozenges by heating the lozenge base under vacuum to remove excess water.
- the lozenge base may be a sugar-based or sugar alcohol-based composition. If the lozenge base is sugar-based, it may comprise a single sugar (eg sucrose) or a mixture of sugars (eg a mixture of sucrose and glucose). If the lozenge base is sugar-alcohol based it may comprise sorbitol, xylitol, maltitol, maltitol syrup, lactitol, mannitol or mixtures thereof which may be in the form of the free sugar alcohols, derivatives thereof or mixtures thereof.
- One preferred lozenge base comprises an approximately equimolar mixture of alpha-D-glucopyranosyl-1 ,6-D-sorbitol and alpha-D-glucosopyranosyl-1 ,1-D-mannitol (isomalt) optionally in conjunction with a hydrogenated glucose syrup such as lycasin.
- the lozenge base is preferably heated to a temperature in the range 110 to 170°C under vacuum to remove water to give a moisture content which is preferably less than 2%, more preferably less than 1 % before the remaining components of the pharmaceutical lozenge formulation are added.
- the remaining ingredients may be blended into the lozenge base mixture as powders or liquids. Powders may be granulated prior to the mixing step.
- the molten mixture may then be passed to individual moulds in which each lozenge is formed or may be drawn into a continuous cylindrical mass from which the individual lozenges are formed.
- the lozenges are then cooled, subjected to a visual check and packed into suitable packaging.
- suitable packaging is a blister pack of a water-impermeable plastics material (eg polyvinylchloride) closed by a metallic eg aluminium foil. The patient removes the lozenge by applying pressure to the blister to force the lozenge to rupture and pass through the metal foil seal. Lozenges will normally be sucked by the patient to release the
- Masticable solid dose formulations may be made by the methods used to prepare chewable candy products or chewing gums.
- a chewable solid dosage form may be prepared from an extruded mixture of sugar and glucose syrup to which the NSAID has been added with optional addition of whipping agents, humectants, lubricants, flavours and colourings.
- whipping agents humectants
- lubricants lubricants
- flavours and colourings See Pharmaceutical Dosage Forms: Tablets, Volume 1 , Second Edition edited by H A Lieberma ⁇ , L Lachman and J B Schwartz published in 1989).
- Liquid and spray formulations may be prepared by dissolving or suspending the NSAID in a liquid medium which may also contain other ingredients such as stabilising agents, buffering agents, flavourings, sweeteners, colouring agents, buffering agents, flavourings, sweeteners, colouring agents and preservatives.
- the formulation may then be packaged into an appropriate container.
- a spray may be prepared by dissolving water soluble components in water and non-water soluble ingredients in a co-solvent (eg alcohol). The two phases are then mixed and the resulting mixture filtered and placed into dispensing containers.
- the dispensing containers may be fitted with a metered, manually-operated spray mechanism or the dispenser may contain a pressurised propellant and be fitted with a suitable dispensing valve.
- compositions which can be sucked or chewed by the patient and which slowly release the NSAID and any active ingredient and/or burn-masking agent.
- NSAID, active ingredient and/or burn-masking agent then passes over the mucous membrane of the throat where some is absorbed providing topical relief.
- the unabsorbed NSAID and active ingredient is then ingested by the patient and absorbed into the blood stream.
- the NSAID and active ingredient so absorbed can act systematically in addition to the relief that comes from the topical application of NSAID and active ingredient to the mucous membrane of the throat.
- a second form of preferred formulations for use in the present invention are sprays which are administered so that the liquid composition is brought into contact with the mucus membrane of the throat so that some of the active components of the composition (NSAID and other active ingredients)
- NSAID and active ingredient is absorbed providing topical relief.
- Ingestion of the remainder of the liquid composition then means that the unabsorbed NSAID and active ingredient can be absorbed in to the blood stream to provide systemic relief in addition to the relief that comes from the topical application of the NSAID and active ingredient to the mucous membrane of the throat.
- Lozenges containing racemic ketoprofen (12.5 mg per lozenge) were prepared by heating the solids from a 1 :1 mixture of sugar and liquid glucose to 140° and applying a vacuum to reduce the water content of the mixture. The NSAID was added and the resulting mixture was cooled and formed into a continuous cylindrical mass from which the individual lozenges were formed each weighing 2350 mg. The individual solid lozenges were visually inspected and then packed. The resulting lozenges were found to provide palatable, stable and effective treatment for sore throats.
- lozenges were made containing the sodium salt of diclofenac (6.25 milligrammes per lozenge).
- lozenges were made containing piroxicam (20 milligrammes per lozenge).
- lozenges were made containing indomethacin (6.25 milligrammes per lozenge).
- a mixture of an NSAID, sorbitol and glycerin was dissolved in aqueous alcohol to provide a pharmaceutical formulation which can be packed into a dispensing container fitted with a metered manually-operated spray mechanism which enables the formulation to be sprayed on to the mucous membrane of the throat as a fine spray.
- a pharmaceutical lozenge formulation is prepared containing the following components expressed in milligrams per lozenge. Ketoprofen q.v.
- the ketoprofen and calcium carbonate are blended for two minutes and the blend granulated with a solution of the polyvinylpyrrolidine in isopropanol.
- the granules are dried and the colloidal silicon dioxide and magnesium stearate are added and the resulting mixture blended for five minutes.
- a molten lozenge base is prepared by dissolving the isomalt in the minimum amount of water.
- the lycasin is added and the mixture heated at 110-120°C.
- the mixture is then heated to 145°C under vacuum to remove water to give the molten lozenge base.
- the blended granule and the flavourings are then added to the molten lozenge base.
- the resulting mixture is cooled and formed into a continuous cylindrical mass from which individual lozenges are prepared.
- the NSAID will be present in the compositions of Examples 7 to 12 at the dose which will be known by those skilled in the art as appropriate for the
- the component identified in Examples 7 to 9 as "Active ingredient” can be any one or more of the one or more active ingredients selected from an antihistamine, a cough suppressant, a decongestant, an expectorant, a muscle relaxant, a centrally acting analgesic, a local anaesthetic, an antibacterial compound, an antiviral compound, minerals and vitamins, particularly any one or more of the compounds specifically identified hereinbefore.
- Lozenges are prepared containing the following ingredients expressed as the weight in milligrammes per lozenge.
- the mixture of the sugar and liquid glucose is heated to 140° and a vacuum applied to reduce the water content of the mixture.
- the flavouring is added in a sealed vessel.
- the flurbiprofen, the active ingredient and the calcium carbonate are blended and the blend added to the remainder of the ingredients.
- the resulting mixture is cooled and formed into a continuous cylindrical mass from which the individual lozenges are formed.
- the individual solid lozenges are visually inspected and then packed.
- the resulting lozenges provide palatable, stable and effective treatment for the symptoms of colds and flu particularly including sore throats.
- lozenges containing combinations of the active ingredients with ibuprofen, naproxen, ketoprofen, diclofenac, piroxicam and indomethacin can be prepared.
- a mixture of an NSAID, the active ingredient, sorbitol and glycerin is dissolved in aqueous alcohol to provide a pharmaceutical formulation which can be packed into a dispensing container fitted with a metered manually-operated spray mechanism which enables the formulation to be sprayed on to the mucous membrane of the throat as a fine spray.
- a pharmaceutical lozenge formulation is prepared containing the following components expressed in milligrams per lozenge.
- the NSAID, the active ingredient and calcium carbonate are blended for two minutes and the blend granulated with a solution of the polyvinylpyrrolidine in isopropanol.
- the granules are dried and the colloidal silicon dioxide and magnesium stearate are added and the resulting mixture blended for five minutes.
- a molten lozenge base is prepared by dissolving the isomalt in the minimum amount of water.
- the lycasin is added and the mixture heated at 110-120°C.
- the mixture is then heated to 145°C under vacuum to remove water to give the molten lozenge base.
- the blended granule and the anethole are then added to the molten lozenge base.
- the resulting mixture is cooled and formed into a continuous cylindrical mass from which individual lozenges are prepared.
- Example 9 lozenges containing combinations of the active ingredients with ibuprofen, naproxen, ketoprofen, diclofenac, piroxicam and indomethacin can be prepared.
- Lozenges are prepared containing the following ingredients expressed as the weight in milligrammes per lozenge.
- the mixture of sugar and liquid glucose is heated to 140°C and a vacuum applied to reduce the water content of the mixture.
- the flavouring is added in a sealed vessel.
- the flurbiprofen and calcium carbonate are blended and the blend and flavourings are added to the remainder of the ingredients.
- the resulting mixture is cooled and formed into a continuous cylindrical mass from which the individual lozenges are formed.
- the individual solid lozenges were visually inspected and then packed.
- the resulting lozenges provide palatable, stable and effective treatment for sore throats.
- lozenges containing anethole with ibuprofen, naproxen, ketoprofen, diclofenac, piroxicam and indomethacin can be prepared.
- a mixture of an NSAID, anethole, sorbitol and glycerin is dissolved in aqueous alcohol to provide a pharmaceutical formulation which can be packed into a dispensing container fitted with a metered manually-operated spray mechanism which enables the formulation to be sprayed on to the mucous membrane of the throat as a fine spray.
- a pharmaceutical lozenge formulation is prepared containing the following components expressed in milligrams per lozenge.
- Anethole q.v The flurbiprofen and calcium carbonate are blended for two minutes and the blend granulated with a solution of the polyvinylpyrrolidine in isopropanol. The granules are dried and the colloidal silicon dioxide and magnesium stearate are added and the resulting mixture blended for five minutes.
- a molten lozenge base is prepared by dissolving the isomalt in the minimum amount of water. The lycasin is added and the mixture heated at
- the mixture is then heated to 145°C under vacuum to remove water to give the molten lozenge base.
- the blended granule and the anethole are then added to the molten lozenge base.
- the resulting mixture is cooled and formed into a continuous cylindrical mass from which individual lozenges are prepared.
- Example 12 lozenges containing anethole with ibuprofen, naproxen, ketoprofen, diclofenac, piroxicam and indomethacin can be prepared.
- the effectiveness of the treatment can be demonstrated by means of clinical trials in which patients suffering from sore throats are administered the formulations described in any one of the Examples or a placebo.
- the patient is asked to assess the effectiveness of the treatment on parameters such as the relief of the pain associated with the sore throat, the reduction in the swelling of the throat and/or the improvement in swallowing following treatment.
- the patients are also examined by a clinician to determine the amount of tonsillopharyngitis.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU81079/98A AU8107998A (en) | 1997-05-22 | 1998-05-22 | Pharmaceutical compositions |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9710527.4 | 1997-05-22 | ||
GBGB9710505.0A GB9710505D0 (en) | 1997-05-22 | 1997-05-22 | Pharmaceutical compositions |
GBGB9710544.9A GB9710544D0 (en) | 1997-05-22 | 1997-05-22 | Medical treatment |
GB9710544.9 | 1997-05-22 | ||
GB9710505.0 | 1997-05-22 | ||
GBGB9710527.4A GB9710527D0 (en) | 1997-05-22 | 1997-05-22 | Pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998052540A1 true WO1998052540A1 (en) | 1998-11-26 |
Family
ID=27268849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/003179 WO1998052540A1 (en) | 1997-05-22 | 1998-05-22 | Pharmaceutical compositions |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU8107998A (en) |
WO (1) | WO1998052540A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028533A2 (en) * | 1999-10-19 | 2001-04-26 | Kain Kevin C | PRODUCTS AND METHODS FOR ACTIVATING PPARη-RXR AND UP-REGULATING MONOCYTE/MACROPHAGE CD36 FOR THE TREATMENT OF MALARIA |
WO2002066029A2 (en) * | 2001-02-21 | 2002-08-29 | Universiteit Gent | Antiprotozoal methods, compositions and feedstuffs |
US6558618B1 (en) * | 1999-04-27 | 2003-05-06 | James L Dent, Jr. | Anti-infection formulation and delivery method |
WO2003089007A1 (en) * | 2002-04-22 | 2003-10-30 | Adcock Ingram Intellectual Property (Proprietary) Limited | Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu |
WO2004019905A1 (en) * | 2002-08-29 | 2004-03-11 | Novadel Pharma Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
EP1405646A2 (en) * | 2002-10-02 | 2004-04-07 | Yung Shin Pharm. Ind. Co. Ltd. | Pharmaceutically acceptable salts of local anaesthetics with anti-inflammatory compounds and methods for preparing the same |
WO2004060360A1 (en) * | 2003-01-03 | 2004-07-22 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Use of active ingredients for the prophylaxis and/or therapy of viral diseases |
WO2005074885A1 (en) | 2004-02-03 | 2005-08-18 | Philippe Perovitch | Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method |
WO2005079747A1 (en) * | 2004-02-13 | 2005-09-01 | Therapicon Srl | Pharmaceutical preparation for the oral cavity |
WO2006092569A1 (en) | 2005-03-01 | 2006-09-08 | Reckitt Benckiser Healthcare (Uk) Limited | Production process for nsaid-containing lozenges, their compositions, their medicinal use |
MY138409A (en) * | 2003-11-19 | 2009-05-29 | Yung Shin Pharm Ind Co Ltd | Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same |
US7588793B1 (en) | 1998-06-05 | 2009-09-15 | Cadbury Adams Usa, Llc | Enhanced flavoring compositions containing N-ethyl-p-menthane-3-carboxamide and method of making and using same |
US8097271B2 (en) | 2004-08-11 | 2012-01-17 | Kraft Foods Global Brands Llc | Warming compositions and delivery systems therefor |
WO2012080718A1 (en) * | 2010-12-15 | 2012-06-21 | Reckitt Benckiser Healthcare International Limited | Novel pharmaceutical formulation comprising nsaid and cyclodextrin |
DE102011111944A1 (en) * | 2011-08-29 | 2013-02-28 | Richard A. Huthmacher | Use of diclofenac for the prevention and treatment of influenza infections as well as disease symptoms caused by influenza infections |
US8623882B2 (en) | 2012-02-06 | 2014-01-07 | Innovative Med Concepts, LLC | Aciclovir and diclofenac combination therapy for functional somatic syndromes |
US8846007B2 (en) | 2005-12-23 | 2014-09-30 | Intercontinental Great Brands Llc | Compositions providing a heating sensation for oral or dermal delivery |
US9078816B2 (en) | 1997-10-01 | 2015-07-14 | Suda Ltd. | Buccal, polar and non-polar spray containing ondansetron |
EP4017488A4 (en) * | 2019-08-22 | 2024-01-10 | Applied Biological Laboratories, Inc. | Compositions and methods using non-steroidal anti-inflammatory drugs |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62298528A (en) * | 1986-06-16 | 1987-12-25 | Yutaka Mizushima | Troche for remedy of pharyngeal pain |
WO1991002512A1 (en) * | 1989-08-17 | 1991-03-07 | Sepracor, Inc. | Buccal composition containing s(+) flurbiprofen or ketoprofen |
JPH0426618A (en) * | 1990-05-21 | 1992-01-29 | Japan Tobacco Inc | Troche |
WO1994013280A1 (en) * | 1992-12-04 | 1994-06-23 | Mayor Pharmaceutical Laboratories, Inc. | Sprayable analgesic composition and method of use |
WO1995023591A1 (en) * | 1994-03-03 | 1995-09-08 | The Procter & Gamble Company | Oral vehicle compositions |
WO1996007412A1 (en) * | 1994-09-02 | 1996-03-14 | Virginia Commonwealth University | Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer |
US5567733A (en) * | 1995-04-27 | 1996-10-22 | Dishler; Jon G. | Irritation relief using nonsteroidal anti-inflammatory compounds |
WO1997018802A1 (en) * | 1995-11-22 | 1997-05-29 | The Boots Company Plc | Pharmaceutical compositions comprising flurbiprofen |
WO1997038662A2 (en) * | 1996-04-12 | 1997-10-23 | Flemington Pharmaceutical Corporation | Buccal polar spray or capsule |
WO1997038663A2 (en) * | 1996-04-12 | 1997-10-23 | Flemington Pharmaceutical Corporation | Buccal, non-polar spray or capsule |
-
1998
- 1998-05-22 AU AU81079/98A patent/AU8107998A/en not_active Abandoned
- 1998-05-22 WO PCT/EP1998/003179 patent/WO1998052540A1/en active Application Filing
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62298528A (en) * | 1986-06-16 | 1987-12-25 | Yutaka Mizushima | Troche for remedy of pharyngeal pain |
WO1991002512A1 (en) * | 1989-08-17 | 1991-03-07 | Sepracor, Inc. | Buccal composition containing s(+) flurbiprofen or ketoprofen |
JPH0426618A (en) * | 1990-05-21 | 1992-01-29 | Japan Tobacco Inc | Troche |
WO1994013280A1 (en) * | 1992-12-04 | 1994-06-23 | Mayor Pharmaceutical Laboratories, Inc. | Sprayable analgesic composition and method of use |
WO1995023591A1 (en) * | 1994-03-03 | 1995-09-08 | The Procter & Gamble Company | Oral vehicle compositions |
WO1996007412A1 (en) * | 1994-09-02 | 1996-03-14 | Virginia Commonwealth University | Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer |
US5567733A (en) * | 1995-04-27 | 1996-10-22 | Dishler; Jon G. | Irritation relief using nonsteroidal anti-inflammatory compounds |
US5567733B1 (en) * | 1995-04-27 | 1999-08-24 | Jon G Dishler | Irritation relief using nonsteroidal anti-inflammatory compounds |
WO1997018802A1 (en) * | 1995-11-22 | 1997-05-29 | The Boots Company Plc | Pharmaceutical compositions comprising flurbiprofen |
WO1997038662A2 (en) * | 1996-04-12 | 1997-10-23 | Flemington Pharmaceutical Corporation | Buccal polar spray or capsule |
WO1997038663A2 (en) * | 1996-04-12 | 1997-10-23 | Flemington Pharmaceutical Corporation | Buccal, non-polar spray or capsule |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Week 8822, Derwent World Patents Index; AN 88-149738 [22], XP002078973 * |
DATABASE WPI Week 9211, Derwent World Patents Index; AN 92-084353 [11], XP002078972 * |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9078816B2 (en) | 1997-10-01 | 2015-07-14 | Suda Ltd. | Buccal, polar and non-polar spray containing ondansetron |
US7588793B1 (en) | 1998-06-05 | 2009-09-15 | Cadbury Adams Usa, Llc | Enhanced flavoring compositions containing N-ethyl-p-menthane-3-carboxamide and method of making and using same |
US6558618B1 (en) * | 1999-04-27 | 2003-05-06 | James L Dent, Jr. | Anti-infection formulation and delivery method |
WO2001028533A3 (en) * | 1999-10-19 | 2001-09-20 | Kevin C Kain | PRODUCTS AND METHODS FOR ACTIVATING PPARη-RXR AND UP-REGULATING MONOCYTE/MACROPHAGE CD36 FOR THE TREATMENT OF MALARIA |
WO2001028533A2 (en) * | 1999-10-19 | 2001-04-26 | Kain Kevin C | PRODUCTS AND METHODS FOR ACTIVATING PPARη-RXR AND UP-REGULATING MONOCYTE/MACROPHAGE CD36 FOR THE TREATMENT OF MALARIA |
WO2002066029A2 (en) * | 2001-02-21 | 2002-08-29 | Universiteit Gent | Antiprotozoal methods, compositions and feedstuffs |
WO2002066029A3 (en) * | 2001-02-21 | 2003-02-20 | Univ Gent | Antiprotozoal methods, compositions and feedstuffs |
WO2003089007A1 (en) * | 2002-04-22 | 2003-10-30 | Adcock Ingram Intellectual Property (Proprietary) Limited | Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu |
WO2004019905A1 (en) * | 2002-08-29 | 2004-03-11 | Novadel Pharma Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
EP1405646A3 (en) * | 2002-10-02 | 2004-04-21 | Yung Shin Pharm. Ind. Co. Ltd. | Pharmaceutically acceptable salts of local anaesthetics with anti-inflammatory compounds and methods for preparing the same |
EP1405646A2 (en) * | 2002-10-02 | 2004-04-07 | Yung Shin Pharm. Ind. Co. Ltd. | Pharmaceutically acceptable salts of local anaesthetics with anti-inflammatory compounds and methods for preparing the same |
WO2004060360A1 (en) * | 2003-01-03 | 2004-07-22 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Use of active ingredients for the prophylaxis and/or therapy of viral diseases |
MY138409A (en) * | 2003-11-19 | 2009-05-29 | Yung Shin Pharm Ind Co Ltd | Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same |
WO2005074885A1 (en) | 2004-02-03 | 2005-08-18 | Philippe Perovitch | Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method |
EP1711162B1 (en) * | 2004-02-03 | 2017-11-01 | Philippe Perovitch | Composition for use in the local treatment of oropharyngeal conditions comprising ibuprofen or ketoprofen |
US8846083B2 (en) | 2004-02-03 | 2014-09-30 | Philippe Perovitch | Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method |
WO2005079747A1 (en) * | 2004-02-13 | 2005-09-01 | Therapicon Srl | Pharmaceutical preparation for the oral cavity |
US8101208B2 (en) | 2004-08-11 | 2012-01-24 | Kraft Foods Global Brands Llc | Sensate compositions and delivery systems therefor |
US8097271B2 (en) | 2004-08-11 | 2012-01-17 | Kraft Foods Global Brands Llc | Warming compositions and delivery systems therefor |
AU2006219777B2 (en) * | 2005-03-01 | 2010-07-01 | Reckitt Benckiser Healthcare (Uk) Limited | Production process for NSAID-containing lozenges, their compositions, their medicinal use |
EP1853220B1 (en) | 2005-03-01 | 2017-08-16 | Reckitt Benckiser Healthcare (UK) Limited | Production process for nsaid-containing lozenges, their compositions, their medicinal use |
WO2006092569A1 (en) | 2005-03-01 | 2006-09-08 | Reckitt Benckiser Healthcare (Uk) Limited | Production process for nsaid-containing lozenges, their compositions, their medicinal use |
EP3284458A1 (en) * | 2005-03-01 | 2018-02-21 | Reckitt Benckiser Healthcare (UK) Limited | Production process for nsaid-containing lozenges, their compositions, their medicinal use |
EP2210587A1 (en) * | 2005-03-01 | 2010-07-28 | Reckitt Benckiser Healthcare (UK) Limited | Production process for NSAID-containing lozenges, their compositions, their medicinal use |
KR101358687B1 (en) | 2005-03-01 | 2014-02-07 | 레킷트 벵키저 헬스케어(유케이)리미티드 | Production process for NSAID-containing lozenges and a pharmaceutical lozenge formulation obtained therfrom |
EP3284458B1 (en) | 2005-03-01 | 2021-06-16 | Reckitt Benckiser Healthcare (UK) Limited | Production process for nsaid-containing lozenges |
US10328039B2 (en) | 2005-03-01 | 2019-06-25 | Reckiit Benckiser Healthcare (Uk) Limited | Production process for NSAID-containing lozenges, their compositions, their medicinal use |
JP2008531664A (en) * | 2005-03-01 | 2008-08-14 | レキット ベンキーザー ヘルスケア (ユーケイ) リミテッド | Method for producing NSAID-containing lozenge, composition thereof, medical use thereof |
US10933040B2 (en) | 2005-03-01 | 2021-03-02 | Reckitt Benckiser Healthcare (Uk) Limited | Production process for NSAID-containing lozenges, their compositions, their medicinal use |
US8846007B2 (en) | 2005-12-23 | 2014-09-30 | Intercontinental Great Brands Llc | Compositions providing a heating sensation for oral or dermal delivery |
US10363316B2 (en) | 2010-12-15 | 2019-07-30 | Reckitt Benckiser Healthcare (Uk) Limited | Pharmaceutical formulation comprising NSAID and cyclodextrin |
US9138482B2 (en) | 2010-12-15 | 2015-09-22 | Reckitt Benckiser Healthcare International Limited | Pharmaceutical formulation comprising NSAID and cyclodextrin |
WO2012080718A1 (en) * | 2010-12-15 | 2012-06-21 | Reckitt Benckiser Healthcare International Limited | Novel pharmaceutical formulation comprising nsaid and cyclodextrin |
WO2013030058A1 (en) | 2011-08-29 | 2013-03-07 | Huthmacher Richard A | Use of diclofenac |
DE102011111944A1 (en) * | 2011-08-29 | 2013-02-28 | Richard A. Huthmacher | Use of diclofenac for the prevention and treatment of influenza infections as well as disease symptoms caused by influenza infections |
US8623882B2 (en) | 2012-02-06 | 2014-01-07 | Innovative Med Concepts, LLC | Aciclovir and diclofenac combination therapy for functional somatic syndromes |
US9682051B2 (en) | 2012-02-06 | 2017-06-20 | Innovative Med Concepts, LLC | Acyclovir and meloxicam combination therapy for functional somatic syndromes |
US9642824B2 (en) | 2012-02-06 | 2017-05-09 | Innovative Med Concepts, LLC | Valaciclovir and diclofenac combination therapy for functional somatic syndromes |
US9259405B2 (en) | 2012-02-06 | 2016-02-16 | Innovative Med Concepts, LLC | Method of treating functional somatic syndromes with combination of famciclovir and diclofenac |
EP2965759A1 (en) | 2012-02-06 | 2016-01-13 | William L. Pridgen | Antiviral compound and cox-2 inhibitor combination therapy for functional somatic syndromes |
US9980932B2 (en) | 2012-02-06 | 2018-05-29 | Innovative Med Concepts, LLC | Valaciclovir and meloxicam combination therapy for functional somatic syndromes |
US10034846B2 (en) | 2012-02-06 | 2018-07-31 | Innovative Med Concepts, LLC | Famciclovir and celecoxib combination therapy for functional somatic syndromes |
US10251853B2 (en) | 2012-02-06 | 2019-04-09 | Innovative Med Concepts, LLC | Synergistic famciclovir and celecoxib combination therapy for functional somatic syndromes |
US9173863B2 (en) | 2012-02-06 | 2015-11-03 | Innovative Med Concepts, LLC | Antiviral compound and COX-2 inhibitor combination therapy for functional somatic syndromes, including combination of famciclovir and celecoxib |
US9040546B2 (en) | 2012-02-06 | 2015-05-26 | Innovative Med Concepts, LLC | Method of treating functional somatic syndromes with combination of famciclovir and celecoxib |
US10543184B2 (en) | 2012-02-06 | 2020-01-28 | Innovative Med Concepts, LLC | Method to treat functional somatic syndromes with combination of aciclovir and celecoxib |
US10632087B2 (en) | 2012-02-06 | 2020-04-28 | Innovative Med Concepts, LLC. | Famciclovir and meloxicam combination therapy for functional somatic syndromes |
US8987282B2 (en) | 2012-02-06 | 2015-03-24 | Innovative Med Concepts, LLC | Acyclovir and meloxicam combination therapy for functional somatic syndromes |
US8809351B2 (en) | 2012-02-06 | 2014-08-19 | Innovative Med Concepts, LLC. | Antiviral compound and cox-2 inhibitor combination therapy for functional somatic syndromes, including combination of famciclovir and celecoxib |
US11096912B2 (en) | 2012-02-06 | 2021-08-24 | Virios Therapeutics, Inc. | Valaciclovir and celecoxib combination for functional somatic syndromes |
EP4017488A4 (en) * | 2019-08-22 | 2024-01-10 | Applied Biological Laboratories, Inc. | Compositions and methods using non-steroidal anti-inflammatory drugs |
Also Published As
Publication number | Publication date |
---|---|
AU8107998A (en) | 1998-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5889057A (en) | Flurbiprofen lozenge for the treatment of sore throat | |
WO1998052545A1 (en) | Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat | |
WO1998052540A1 (en) | Pharmaceutical compositions | |
CA2290830C (en) | Process | |
US6277409B1 (en) | Protective coating for tablet | |
US20060073189A1 (en) | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements | |
GB2338896A (en) | Chewable oral dosage unit with multilpe reservoirs | |
NO323022B1 (en) | Use of a composition comprising an analgesic combination, oral formulation, and method of preparing the formulation. | |
US7887832B2 (en) | Popping oral pharmaceutical compositions | |
EP1853220B2 (en) | Production process for nsaid-containing lozenges, their compositions, their medicinal use | |
EP2892528B1 (en) | Pharmaceutical compositions comprising flurbiprofen | |
US20080187589A1 (en) | Multi-modal delivery via transmucosal and gastro-intestinal absorption of antihistamines and symptom relief | |
WO2012146314A1 (en) | Thin gelatin capsules for rapid drug release in the mouth | |
Namdev et al. | Unexplored Potential of Medicated Candies And Lozenges as a Drug Delivery System | |
EP4415686A1 (en) | Dextrose tablets with improved mouthfeel | |
MXPA99010548A (en) | Process for making flurbiprofen lozenges | |
Shilpa | Medicated chewing gum: a novel drug delivery system for the treatmnet of cough |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998549997 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |